Document:

Form of subordinated convertible promissory note

 Exhibit 10.3 
 THIS NOTE HAS BEEN, AND THE SHARES OF COMMON STOCK OR NEW SECURITIES WHICH MAY BE RECEIVED PURSUANT TO THE CONVERSION OF THIS NOTE WILL BE, ACQUIRED SOLELY FOR INVESTMENT AND NOT WITH A VIEW TO, OR FOR
RESALE IN CONNECTION WITH, ANY DISTRIBUTION THEREOF. NEITHER THIS NOTE NOR SUCH SHARES OF COMMON STOCK OR NEW SECURITIES HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR QUALIFIED UNDER ANY STATE SECURITIES
LAWS. SUCH SECURITIES MAY NOT BE SOLD OR OFFERED FOR SALE IN THE ABSENCE OF SUCH REGISTRATION OR QUALIFICATION OR AN OPINION OF COUNSEL IN FORM AND SUBSTANCE REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH DISPOSITION IS EXEMPT FROM THE
REGISTRATION REQUIREMENTS OF THE ACT AND ANY REGISTRATION OR QUALIFICATION REQUIREMENTS UNDER APPLICABLE STATE SECURITIES LAWS. 
 THIS NOTE IS
SUBJECT TO A SUBORDINATION AGREEMENT DATED AS OF THE DATE HEREOF AMONG THE ADMINISTRATIVE AGENT NAMED THEREIN AND THE PURCHASERS NAME THEREIN (INCLUDING THE HOLDER), AND ACKNOWLEDGED BY THE COMPANY WHICH, AMONG OTHER THINGS, SUBORDINATES THE
COMPANY’S OBLIGATIONS TO THE PURCHASER TO THE COMPANY’S OBLIGATIONS TO THE SENIOR LENDERS AS FURTHER DESCRIBED THEREIN. 
 RIB-X PHARMACEUTICALS, INC. 
 Subordinated Convertible Promissory Note (the
“Note”) 
  

			
	 $             (the “Principal
Amount”)
	  	New York, NY
		  	January 8, 2009

 Rib-X Pharmaceuticals, Inc., a Delaware corporation (the “Company”), for value received,
hereby promises to pay to             or its assigns (collectively, the “Holder”) the Principal Amount together with interest (computed on the basis of a 365-day year for
the actual number of days elapsed) accruing daily and compounding quarterly from the date hereof on the unpaid balance of the Principal Amount from time to time outstanding at the rate of ten percent (10%) per annum (the
“Interest”) until the Principal Amount and Interest are paid in full or converted as provided herein. Capitalized terms used herein but not defined shall have the meanings given to such terms in the Subordinated Convertible
Promissory Note Purchase Agreement (the “Note Purchase Agreement”), dated as of January 8, 2009, by and among the Company and the Purchasers (as defined therein). It is acknowledged that the Subordinated Convertible Promissory
Notes issued pursuant to the Note Purchase Agreement, of which this Note is one, are being issued at the First Closing in an aggregate amount of approximately $25 million (such Subordinated Convertible Promissory Notes, the “Initial
Notes”) and the holders of such notes, collectively, the “Noteholders”). It is further acknowledged that the Company may issue additional Subordinated Convertible Promissory Notes to the Noteholders in an aggregate

 
amount of $10 million pursuant to the terms and conditions of the Note Purchase Agreement at the Second Closing (the “Subsequent Notes” and together with the Initial Notes the
“Notes”). 
 Subject to Section 2 of this Note, the Principal Amount and the Interest thereon,
unless previously converted or repaid as provided herein, shall be due and payable by the Company in cash on January 8, 2014 (the “Maturity Date”). Payments hereunder are to be made without defense, setoff, counterclaim or
recoupment in lawful money of the United States of America in same day or immediately available funds to the account of the Holder specified from time to time by the Holder to the Company. 

Subject to any applicable notice periods, all parties to this Note, including the Company and any sureties, endorsers, or guarantors,
hereby waive protest, presentment, notice of dishonor, and notice of acceleration of maturity and agree to continue to remain bound for the payment of the Principal Amount, the Interest and all other sums due under this Note notwithstanding any
change or changes by way of release, surrender, exchange, modification or substitution of any security for this Note or by way of any extension or extensions of time for the payment of the Principal Amount and the Interest and all such parties waive
all and every kind of notice of such change or changes and agree that the same may be without notice or consent of any of them. 

Following an Event of Default (as defined herein), the Noteholders who hold Notes representing at least sixty percent (60%) of the
aggregate principal amount owed by the Company pursuant to the then outstanding Notes (the “Majority Noteholders”) may (i) elect to pursue the rights of the Noteholders under this Note and all other Notes and
(ii) collectively employ an attorney to enforce their rights and remedies under this Note and all other Notes and the Company and any surety, guarantor or endorser of this Note hereby agree to pay to the Noteholders’ reasonable
attorneys’ fees, plus all other reasonable expenses incurred by the Noteholders in exercising any such rights and remedies. The rights and remedies of the Noteholders as provided in this Note and all other Notes shall be cumulative and each
such right or remedy may be pursued singly, successively, or together against any other funds, property or security held by the Noteholders for payment or security, in the sole discretion of the Majority Noteholders. The failure to exercise any such
right or remedy shall not be a waiver or release of such rights or remedies or the right to exercise any of them at another time. 
 As used herein, the term “Base Conversion Price” shall mean the Conversion Price (as defined in, and as adjusted pursuant to, the Company’s Fifth Amended and Restated Certificate of
Incorporation (the “Charter”)) of the Company’s Series C Preferred Stock; provided, however, if at any time there are no longer any shares of the Company’s Series C Preferred Stock outstanding, the Base
Conversion Price shall thereafter be adjusted as if one (1) share of Series C Preferred Stock continued to be outstanding. 
  

	1.	Conversion. 

  

	 	(a)	 Failure to Purchase Subsequent Notes. In the event that the Holder elects to acquire less than all of the Subsequent Notes that the Holder is
required to acquire pursuant to Article I of the Note Purchase Agreement, the amount then outstanding under this Note including any accrued but unpaid Interest (the “Outstanding Amount”) shall automatically convert into the number
of shares of 

  
 -2-

	 	
common stock of the Company, par value $0.001 per share (“Common Stock”), that is equal to (i) the Outstanding Amount divided by (ii) Base Conversion Price as of the
date of such conversion. 

  

	 	(b)	Qualified Financing. In the event that the Company consummates an equity financing (except for a financing solely in connection with a business development
transaction with a strategic partner or a disposition, transfer or license of the Company’s products or rights) prior to the Maturity Date, in which (i) the Company issues securities that are senior to or pari passu with the Series C
Preferred Stock of the Company (the “New Qualified Securities”) and (ii) the aggregate proceeds to the Company (excluding any amounts converted pursuant to this Note or any other Note) equal or exceed $30,000,000 (a
“Qualified Financing”), the Outstanding Amount shall automatically convert into the number of New Qualified Securities that is equal to (A) the Outstanding Amount divided by (B) the lesser of (1) Base Conversion Price
as of the date of such conversion and (2) ninety percent (90%) of the price per New Qualified Security at which the New Qualified Security is sold to investors in the Qualified Financing. 

 

	 	(c)	Non-Qualified Financing. In the event that the Company consummates an equity financing (except for a financing solely in connection with a business development
transaction with a strategic partner or a disposition, transfer or license of the Company’s products or rights) prior to the Maturity Date, in which the Company’s issues new securities (the “New Non-Qualified Securities”
and together with the New Qualified Securities, the “New Securities”) and the aggregate proceeds to the Company (excluding any amounts converted pursuant to this Note or any other Note) are less than $30,000,000 (a
“Non-Qualified Financing”), the Majority Noteholders shall have the right, but not the obligation, to elect to convert the Outstanding Amount under this Note (and the Outstanding Amounts under all other Notes) into the number of New
Non-Qualified Securities that is equal to (A) the Outstanding Amount under this Note (and the corresponding Outstanding Amounts under all other Notes) divided by (B) the lesser of (1) Base Conversion Price as of the date of such
conversion and (2) ninety percent (90%) of the price per New Non-Qualified Security at which the New Non-Qualified Security is sold to investors in the Non-Qualified Financing. 

 

	 	(d)	Initial Public Offering. In the event that the Company consummates an initial public offering of its Common Stock prior to the Maturity Date (the
“IPO”), the Outstanding Amount shall automatically convert into the number of shares of Common Stock that is equal to (1) the Outstanding Amount divided by (2) the lesser of (y) Base Conversion Price as of the date of
such conversion and (z) seventy-five percent (75%) of the amount per share for which the Company issues securities in the IPO. 

  

	 	(e)	Mechanics of Conversion. 

  

	 	(i)	 In connection with any conversion of the Note pursuant to this Section 1, the Holder shall provide notice to the Company, which shall state
such 

  
 -3-

	 	
Holder’s name or the names of his or its nominees in which such Holder wishes the shares of Common Stock or the New Securities to be issued upon conversion. Promptly following such
conversion the Company shall update the books and records of the Company to evidence the issuance of the applicable shares of Common Stock or New Securities to the Holder. 

 

	 	(ii)	Immediately upon any conversion of the Note pursuant to this Section 1, this Note shall no longer be deemed to be outstanding and all rights of the holder
with respect to this Note shall immediately cease and terminate, except the right of the holder to receive the applicable shares of Common Stock or New Securities to which it is entitled as a result of such conversion. 

 

	 	(iii)	The Company shall pay any and all issue and other taxes that may be payable in respect of any issuance or delivery of the applicable shares of Common Stock or New
Securities upon any conversion of this Note pursuant to this Section 1. The Company shall not, however, be required to pay any tax which may be payable in respect of any transfer involved in the issuance and delivery of the applicable
shares of Common Stock or New Securities in a name other than that of the registered Holder of this Note, and no such issuance or delivery shall be made unless and until the person or entity requesting such issuance has paid to the Company the
amount of any such tax or has established, to the satisfaction of the Company, that such tax has been paid. 

  

	 	(f)	Reservation of Common Stock. During the period within which this Note may be converted pursuant to this Section 1, the Company shall at all times
have authorized and reserved for issuance a sufficient number of shares of its Common Stock to provide for the conversion of the then Outstanding Amount. 

  

	2.	Repayment. 

  

	 	(a)	 Upon a Change of Control or Liquidation. In the event of (a) any liquidation, dissolution or winding up of the affairs of the Company,
(b) any consolidation, merger or other business combination of the Company (other than a consolidation, merger, or combination in which the stockholders of the Corporation immediately prior to the transaction possess more than fifty percent
(50%) of the voting securities of the surviving or resulting entity immediately after the transaction), (c) any sale or disposition of a majority of the Company’s equity interests (calculated on an as-converted basis) to any person or
entity who is not an equityholder of the Company as of the date hereof, (d) any sale, license or disposition of all or substantially all of the assets of the Company or (e) any other event in which the Series B and Series C Liquidation
Preference (as defined in the Charter) would be payable to the holders of Series B Preferred Stock of the Company and Series C Preferred Stock of the Company (each a “Repayment Event”), the Holder shall automatically be entitled to
receive, in full satisfaction of the Company’s repayment obligations under this Note, the greater of (i) the sum of 

  
 -4-

	 	
(y) one and three-quarter times (1.75X) the Principal Amount plus (z) any then accrued but unpaid Interest and (ii) the amount that the Holder would be entitled to receive
if the Outstanding Amount converted into shares of Common Stock immediately prior to the Repayment Event at the Base Conversion Price in effect at the time. 

 

	 	(b)	At Majority Noteholders’ Election. In the event that the Majority Noteholders provide written notice to the Company any time after January 8, 2010
(which date shall automatically be extended until July 8, 2010 if the Company shall enter into an exclusive licensing transaction which provides at least $30,000,000 in up-front net cash proceeds to the Company and is approved by the Board of
Directors (which shall include the approval of at least a majority of the total number of directors designated by the holders of Convertible Preferred Stock and the holders of the Notes) requiring that the Company repay the Notes, the Company shall
promptly (and in any event within ten (10) business days of receipt of such notice) repay the Outstanding Amount under this Note and the corresponding Outstanding Amounts under all other Notes. All such repayments shall be made pro rata among
the Notes based on the amounts then outstanding under each such Note. 

  

	 	(c)	No Prepayment. Except as contemplated by this Section 2, in no event shall the Company have the right or the obligation to repay any portion of the
Principal Amount or any Interest thereon or any portion of the amounts owed by the Company under any other Note prior to the Maturity Date. 

  

	3.	Restrictions on Transfer. This Note and the equity interests into which the Note may be converted, shall not be assigned, sold, pledged, transferred or otherwise
disposed of except in compliance with the terms of the Third Amended and Restated Stockholders Agreement, dated as of June 8, 2006, by and among the Stockholders (as defined therein) and the Company (as amended, the “Stockholders
Agreement”) and only with the prior written consent of the Majority Noteholders. For purposes of Section 3 and Section 4 of the Stockholders Agreement, the Holder shall be deemed to hold the number of shares of
Common Stock into which this Note could be converted pursuant to Section 1. Any shares of Common Stock or New Securities issuable upon a conversion pursuant to Section 1 shall be subject to the terms and conditions of the
Stockholders Agreement that are applicable to the Holder. 

  

	4.	Default. This Note and all amounts due hereunder shall become immediately due and payable in cash at the election of the Majority Noteholders upon the occurrence
at any time of any of the following events of default (individually, an “Event of Default” and collectively, “Events of Default”): 

 

	 	(a)	default in the payment when due of any portion of the Principal Amount or any Interest thereon; 

  
 -5-

	 	(b)	the liquidation, termination of existence, dissolution or the appointment of a receiver or custodian for the Company or any part of its property if such appointment is
not terminated or dismissed within thirty (30) days; 

  

	 	(c)	the institution against the Company or any endorser or guarantor of this Note of any proceedings under the United States Bankruptcy Code or any other federal or state
bankruptcy, reorganization, receivership, insolvency or other similar law affecting the rights of creditors generally, which proceeding is not dismissed within thirty (30) days of filing; 

 

	 	(d)	the institution by the Company or any endorser or guarantor of this Note of any proceedings under the United States Bankruptcy Code or any other federal or state
bankruptcy, reorganization, receivership, insolvency or other similar law affecting the rights of creditors generally or the making by the Company or any endorser or guarantor of this Note of a composition or an assignment or trust mortgage for the
benefit of creditors; 

  

	 	(e)	the material breach of any covenant set forth in the Note Purchase Agreement or this Note which breach remains uncured ten (10) days after written notice thereof
by any Noteholder to the Company; 

  

	 	(f)	the failure of any of the Company’s representations or warranties set forth in Article II of the Note Purchase Agreement to be true and correct (i) in all
respects on the Initial Closing Date (as defined in the Note Purchase Agreement) or (ii) in all material respects on the Second Closing Date (as defined in the Note Purchase Agreement); or 

 

	 	(g)	the occurrence of any event upon which, whether with the giving of notice, the passage of time or otherwise, would allow the Holder or holders of any indebtedness of
the Company or any of its subsidiaries to accelerate or otherwise demand repayment or repurchase prior to the scheduled maturity thereof of any such indebtedness or the acceleration of any such indebtedness. 

Upon the occurrence of an Event of Default, the Holder shall have then, or at any time thereafter, all of the rights and remedies
afforded by the Uniform Commercial Code as from time to time in effect in the State of Delaware or afforded by other applicable law. 
  

	5.	General. 

  

	 	(a)	Successors and Assigns. This Note, and the obligations and rights of the Company hereunder, shall be binding upon and inure to the benefit of the Company, the
Holder, and their respective heirs, successors and permitted assigns. 

  

	 	(b)	Recourse. Recourse under this Note shall be to the Company and its assets only, and in no event to the officers, directors or shareholders of the Company.

  
 -6-

	 	(c)	Changes. Changes in or additions to this Note may be made or compliance with any term, covenant, agreement, condition or provision set forth herein may be
omitted or waived (either generally or in a particular instance and either retroactively or prospectively), only upon written consent of the Company and the Majority Noteholders. 

 

	 	(d)	Governing Law. This Note shall be governed by and construed in accordance with the law of the State of Delaware, excluding the body of law relating to conflict
of laws. Notwithstanding anything to the contrary contained herein, in no event may the effective rate of interest collected or received by the holder hereof exceed that which may be charged, collected or received by the holder under applicable law.

  

	 	(e)	 Notices. All notices, requests, consents and demands shall be made in writing and shall be mailed postage prepaid, or delivered by hand, to the
Company at the Company’s principal offices or to the Holder at the address of the Holder set forth in the Note Purchase Agreement or to such other address as may be furnished in writing to the other party hereto, and in addition may be
delivered by telex, telecopy, electronic mail or facsimile transmission. All notices, requests, consents and other communications hereunder shall be deemed to have been given either (i) if by hand, at the time of the delivery thereof to the
receiving party at the address of such party set forth above, (ii) if made by telex, telecopy, electronic mail or facsimile transmission, at the time that receipt thereof has been acknowledged by electronic confirmation or otherwise,
(iii) if sent by overnight courier, on the next business day following the day such notice is delivered to the courier service, or (iv) if sent by registered or certified mail, on the 3rd business day following the day such mailing is made.

  

	 	(f)	Jurisdiction. THE COMPANY AGREES THAT ANY SUIT FOR THE ENFORCEMENT OF THIS NOTE, THE SUBSCRIPTION AGREEMENT OR ANY OTHER RELATED DOCUMENT MAY BE BROUGHT IN THE
COURTS OF THE STATE OF NEW YORK OR ANY FEDERAL COURT SITTING THEREIN AND CONSENTS TO THE NONEXCLUSIVE JURISDICTION OF SUCH COURTS AND SERVICE OF PROCESS IN ANY SUCH SUIT BEING MADE UPON THE COMPANY AT ITS PRINCIPAL OFFICES. THE COMPANY HEREBY WAIVES
ANY OBJECTION THAT IT MAY NOW OR HEREAFTER HAVE TO THE VENUE OF ANY SUCH SUIT OR ANY SUCH COURT OR THAT SUCH SUIT IS BROUGHT IN AN INCONVENIENT COURT. 

  

	 	(g)	Trial by Jury. The Company hereby waives its right to a jury trial with respect to any action or claim arising out of any dispute in connection with this Note,
any rights or obligations hereunder or the performance of such rights and obligations. 

  

	 	(h)	 To the extent permitted by applicable law, the Company shall not assert, and hereby waives, any claim against any Noteholder and their respective
affiliates, directors, employees, attorneys, agents or sub-agents, for special, indirect, consequential or punitive damages arising out of, in connection with, as a result of

  
 -7-

	 	
or related to, this Note, the transactions contemplated hereby or thereby, the Loan or the use of the proceeds thereof. 

[Remainder of Page Intentionally Left Blank] 

  
 -8-

 IN WITNESS WHEREOF, this Note has been executed and delivered on the date first above
written by the duly authorized representative of the Company. 
  

			
	RIB-X PHARMACEUTICALS, INC.
		
	By:	 	  

		
	Name:	 	  

		
	Title:Form of subordinated convertible promissory note

 Exhibit 10.4 
 THIS NOTE HAS BEEN, AND THE SHARES OF COMMON STOCK OR NEW SECURITIES WHICH MAY BE RECEIVED PURSUANT TO THE CONVERSION OF THIS NOTE WILL BE, ACQUIRED SOLELY FOR INVESTMENT AND NOT WITH A VIEW TO, OR FOR
RESALE IN CONNECTION WITH, ANY DISTRIBUTION THEREOF. NEITHER THIS NOTE NOR SUCH SHARES OF COMMON STOCK OR NEW SECURITIES HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR QUALIFIED UNDER ANY STATE SECURITIES
LAWS. SUCH SECURITIES MAY NOT BE SOLD OR OFFERED FOR SALE IN THE ABSENCE OF SUCH REGISTRATION OR QUALIFICATION OR AN OPINION OF COUNSEL IN FORM AND SUBSTANCE REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH DISPOSITION IS EXEMPT FROM THE
REGISTRATION REQUIREMENTS OF THE ACT AND ANY REGISTRATION OR QUALIFICATION REQUIREMENTS UNDER APPLICABLE STATE SECURITIES LAWS. 
 THIS NOTE IS
SUBJECT TO A SUBORDINATION AGREEMENT DATED AS OF THE DATE HEREOF AMONG THE ADMINISTRATIVE AGENT NAMED THEREIN AND THE PURCHASERS NAME THEREIN (INCLUDING THE HOLDER), AND ACKNOWLEDGED BY THE COMPANY WHICH, AMONG OTHER THINGS, SUBORDINATES THE
COMPANY’S OBLIGATIONS TO THE PURCHASER TO THE COMPANY’S OBLIGATIONS TO THE SENIOR LENDERS AS FURTHER DESCRIBED THEREIN. 
 RIB-X PHARMACEUTICALS, INC. 
 Subordinated Convertible Promissory Note (the
“Note”) 
  

			
	$             (the “Principal Amount”)	  	New York, NY
		  	December 11, 2009

 Rib-X Pharmaceuticals, Inc., a Delaware corporation (the “Company”), for value received,
hereby promises to pay to              or its assigns (collectively, the “Holder”) the Principal Amount together with interest (computed on the basis of a 365-day year for
the actual number of days elapsed) accruing daily and compounding quarterly from the date hereof on the unpaid balance of the Principal Amount from time to time outstanding at the rate of ten percent (10%) per annum (the
“Interest”) until the Principal Amount and Interest are paid in full or converted as provided herein. Capitalized terms used herein but not defined shall have the meanings given to such terms in the Subordinated Convertible
Promissory Note Purchase Agreement (the “Note Purchase Agreement”), dated as of January 8, 2009, by and among the Company and the Purchasers (as defined therein). It is acknowledged that the Subordinated Convertible Promissory
Notes issued pursuant to the Note Purchase Agreement, of which this Note is one, are being issued at the First Closing in an aggregate amount of approximately $25 million (such Subordinated Convertible Promissory Notes, the “Initial
Notes”) and the holders of such notes, collectively, the “Noteholders”). It is further acknowledged that the Company may issue additional Subordinated Convertible Promissory Notes to the Noteholders in an aggregate

 
amount of $10 million pursuant to the terms and conditions of the Note Purchase Agreement at the Second Closing (the “Subsequent Notes” and together with the Initial Notes the
“Notes”). 
 Subject to Section 2 of this Note, the Principal Amount and the Interest thereon,
unless previously converted or repaid as provided herein, shall be due and payable by the Company in cash on January 8, 2014 (the “Maturity Date”). Payments hereunder are to be made without defense, setoff, counterclaim or
recoupment in lawful money of the United States of America in same day or immediately available funds to the account of the Holder specified from time to time by the Holder to the Company. 

Subject to any applicable notice periods, all parties to this Note, including the Company and any sureties, endorsers, or guarantors,
hereby waive protest, presentment, notice of dishonor, and notice of acceleration of maturity and agree to continue to remain bound for the payment of the Principal Amount, the Interest and all other sums due under this Note notwithstanding any
change or changes by way of release, surrender, exchange, modification or substitution of any security for this Note or by way of any extension or extensions of time for the payment of the Principal Amount and the Interest and all such parties waive
all and every kind of notice of such change or changes and agree that the same may be without notice or consent of any of them. 

Following an Event of Default (as defined herein), the Noteholders who hold Notes representing at least sixty percent (60%) of the
aggregate principal amount owed by the Company pursuant to the then outstanding Notes (the “Majority Noteholders”) may (i) elect to pursue the rights of the Noteholders under this Note and all other Notes and
(ii) collectively employ an attorney to enforce their rights and remedies under this Note and all other Notes and the Company and any surety, guarantor or endorser of this Note hereby agree to pay to the Noteholders’ reasonable
attorneys’ fees, plus all other reasonable expenses incurred by the Noteholders in exercising any such rights and remedies. The rights and remedies of the Noteholders as provided in this Note and all other Notes shall be cumulative and each
such right or remedy may be pursued singly, successively, or together against any other funds, property or security held by the Noteholders for payment or security, in the sole discretion of the Majority Noteholders. The failure to exercise any such
right or remedy shall not be a waiver or release of such rights or remedies or the right to exercise any of them at another time. 
 As used herein, the term “Base Conversion Price” shall mean the Conversion Price (as defined in, and as adjusted pursuant to, the Company’s Fifth Amended and Restated Certificate of
Incorporation (the “Charter”)) of the Company’s Series C Preferred Stock; provided, however, if at any time there are no longer any shares of the Company’s Series C Preferred Stock outstanding, the Base
Conversion Price shall thereafter be adjusted as if one (1) share of Series C Preferred Stock continued to be outstanding. 
  

	1.	Conversion. 

  

	 	(a)	 Failure to Purchase Subsequent Notes. In the event that the Holder elects to acquire less than all of the Subsequent Notes that the Holder is
required to acquire pursuant to Article I of the Note Purchase Agreement, the amount then outstanding under this Note including any accrued but unpaid Interest (the “Outstanding Amount”) shall automatically convert into the number
of shares of 

  
 -2-

	 	
common stock of the Company, par value $0.001 per share (“Common Stock”), that is equal to (i) the Outstanding Amount divided by (ii) Base Conversion Price as of the
date of such conversion. 

  

	 	(b)	Qualified Financing. In the event that the Company consummates an equity financing (except for a financing solely in connection with a business development
transaction with a strategic partner or a disposition, transfer or license of the Company’s products or rights) prior to the Maturity Date, in which (i) the Company issues securities that are senior to or pari passu with the Series C
Preferred Stock of the Company (the “New Qualified Securities”) and (ii) the aggregate proceeds to the Company (excluding any amounts converted pursuant to this Note or any other Note) equal or exceed $30,000,000 (a
“Qualified Financing”), the Outstanding Amount shall automatically convert into the number of New Qualified Securities that is equal to (A) the Outstanding Amount divided by (B) the lesser of (1) Base Conversion Price
as of the date of such conversion and (2) ninety percent (90%) of the price per New Qualified Security at which the New Qualified Security is sold to investors in the Qualified Financing. 

 

	 	(c)	Non-Qualified Financing. In the event that the Company consummates an equity financing (except for a financing solely in connection with a business development
transaction with a strategic partner or a disposition, transfer or license of the Company’s products or rights) prior to the Maturity Date, in which the Company’s issues new securities (the “New Non-Qualified Securities”
and together with the New Qualified Securities, the “New Securities”) and the aggregate proceeds to the Company (excluding any amounts converted pursuant to this Note or any other Note) are less than $30,000,000 (a
“Non-Qualified Financing”), the Majority Noteholders shall have the right, but not the obligation, to elect to convert the Outstanding Amount under this Note (and the Outstanding Amounts under all other Notes) into the number of New
Non-Qualified Securities that is equal to (A) the Outstanding Amount under this Note (and the corresponding Outstanding Amounts under all other Notes) divided by (B) the lesser of (1) Base Conversion Price as of the date of such
conversion and (2) ninety percent (90%) of the price per New Non-Qualified Security at which the New Non-Qualified Security is sold to investors in the Non-Qualified Financing. 

 

	 	(d)	Initial Public Offering. In the event that the Company consummates an initial public offering of its Common Stock prior to the Maturity Date (the
“IPO”), the Outstanding Amount shall automatically convert into the number of shares of Common Stock that is equal to (1) the Outstanding Amount divided by (2) the lesser of (y) Base Conversion Price as of the date of
such conversion and (z) seventy-five percent (75%) of the amount per share for which the Company issues securities in the IPO. 

  

	 	(e)	Mechanics of Conversion. 

  

	 	(i)	 In connection with any conversion of the Note pursuant to this Section 1, the Holder shall provide notice to the Company, which shall state
such 

  
 -3-

	 	
Holder’s name or the names of his or its nominees in which such Holder wishes the shares of Common Stock or the New Securities to be issued upon conversion. Promptly following such
conversion the Company shall update the books and records of the Company to evidence the issuance of the applicable shares of Common Stock or New Securities to the Holder. 

 

	 	(ii)	Immediately upon any conversion of the Note pursuant to this Section 1, this Note shall no longer be deemed to be outstanding and all rights of the holder
with respect to this Note shall immediately cease and terminate, except the right of the holder to receive the applicable shares of Common Stock or New Securities to which it is entitled as a result of such conversion. 

 

	 	(iii)	The Company shall pay any and all issue and other taxes that may be payable in respect of any issuance or delivery of the applicable shares of Common Stock or New
Securities upon any conversion of this Note pursuant to this Section 1. The Company shall not, however, be required to pay any tax which may be payable in respect of any transfer involved in the issuance and delivery of the applicable
shares of Common Stock or New Securities in a name other than that of the registered Holder of this Note, and no such issuance or delivery shall be made unless and until the person or entity requesting such issuance has paid to the Company the
amount of any such tax or has established, to the satisfaction of the Company, that such tax has been paid. 

  

	 	(f)	Reservation of Common Stock. During the period within which this Note may be converted pursuant to this Section 1, the Company shall at all times
have authorized and reserved for issuance a sufficient number of shares of its Common Stock to provide for the conversion of the then Outstanding Amount. 

  

	2.	Repayment. 

  

	 	(a)	 Upon a Change of Control or Liquidation. In the event of (a) any liquidation, dissolution or winding up of the affairs of the Company,
(b) any consolidation, merger or other business combination of the Company (other than a consolidation, merger, or combination in which the stockholders of the Corporation immediately prior to the transaction possess more than fifty percent
(50%) of the voting securities of the surviving or resulting entity immediately after the transaction), (c) any sale or disposition of a majority of the Company’s equity interests (calculated on an as-converted basis) to any person or
entity who is not an equityholder of the Company as of the date hereof, (d) any sale, license or disposition of all or substantially all of the assets of the Company or (e) any other event in which the Series B and Series C Liquidation
Preference (as defined in the Charter) would be payable to the holders of Series B Preferred Stock of the Company and Series C Preferred Stock of the Company (each a “Repayment Event”), the Holder shall automatically be entitled to
receive, in full satisfaction of the Company’s repayment obligations under this Note, the greater of (i) the sum of 

  
 -4-

	 	
(y) one and three-quarter times (1.75X) the Principal Amount plus (z) any then accrued but unpaid Interest and (ii) the amount that the Holder would be entitled to receive
if the Outstanding Amount converted into shares of Common Stock immediately prior to the Repayment Event at the Base Conversion Price in effect at the time. 

 

	 	(b)	At Majority Noteholders’ Election. In the event that the Majority Noteholders provide written notice to the Company any time after January 8, 2010
(which date shall automatically be extended until July 8, 2010 if the Company shall enter into an exclusive licensing transaction which provides at least $30,000,000 in up-front net cash proceeds to the Company and is approved by the Board of
Directors (which shall include the approval of at least a majority of the total number of directors designated by the holders of Convertible Preferred Stock and the holders of the Notes) requiring that the Company repay the Notes, the Company shall
promptly (and in any event within ten (10) business days of receipt of such notice) repay the Outstanding Amount under this Note and the corresponding Outstanding Amounts under all other Notes. All such repayments shall be made pro rata among
the Notes based on the amounts then outstanding under each such Note. 

  

	 	(c)	No Prepayment. Except as contemplated by this Section 2, in no event shall the Company have the right or the obligation to repay any portion of the
Principal Amount or any Interest thereon or any portion of the amounts owed by the Company under any other Note prior to the Maturity Date. 

  

	3.	Restrictions on Transfer. This Note and the equity interests into which the Note may be converted, shall not be assigned, sold, pledged, transferred or otherwise
disposed of except in compliance with the terms of the Third Amended and Restated Stockholders Agreement, dated as of June 8, 2006, by and among the Stockholders (as defined therein) and the Company (as amended, the “Stockholders
Agreement”) and only with the prior written consent of the Majority Noteholders. For purposes of Section 3 and Section 4 of the Stockholders Agreement, the Holder shall be deemed to hold the number of shares of
Common Stock into which this Note could be converted pursuant to Section 1. Any shares of Common Stock or New Securities issuable upon a conversion pursuant to Section 1 shall be subject to the terms and conditions of the
Stockholders Agreement that are applicable to the Holder. 

  

	4.	Default. This Note and all amounts due hereunder shall become immediately due and payable in cash at the election of the Majority Noteholders upon the occurrence
at any time of any of the following events of default (individually, an “Event of Default” and collectively, “Events of Default”): 

 

	 	(a)	default in the payment when due of any portion of the Principal Amount or any Interest thereon; 

  
 -5-

	 	(b)	the liquidation, termination of existence, dissolution or the appointment of a receiver or custodian for the Company or any part of its property if such appointment is
not terminated or dismissed within thirty (30) days; 

  

	 	(c)	the institution against the Company or any endorser or guarantor of this Note of any proceedings under the United States Bankruptcy Code or any other federal or state
bankruptcy, reorganization, receivership, insolvency or other similar law affecting the rights of creditors generally, which proceeding is not dismissed within thirty (30) days of filing; 

 

	 	(d)	the institution by the Company or any endorser or guarantor of this Note of any proceedings under the United States Bankruptcy Code or any other federal or state
bankruptcy, reorganization, receivership, insolvency or other similar law affecting the rights of creditors generally or the making by the Company or any endorser or guarantor of this Note of a composition or an assignment or trust mortgage for the
benefit of creditors; 

  

	 	(e)	the material breach of any covenant set forth in the Note Purchase Agreement or this Note which breach remains uncured ten (10) days after written notice thereof
by any Noteholder to the Company; 

  

	 	(f)	the failure of any of the Company’s representations or warranties set forth in Article II of the Note Purchase Agreement to be true and correct (i) in all
respects on the Initial Closing Date (as defined in the Note Purchase Agreement) or (ii) in all material respects on the Second Closing Date (as defined in the Note Purchase Agreement); or 

 

	 	(g)	the occurrence of any event upon which, whether with the giving of notice, the passage of time or otherwise, would allow the Holder or holders of any indebtedness of
the Company or any of its subsidiaries to accelerate or otherwise demand repayment or repurchase prior to the scheduled maturity thereof of any such indebtedness or the acceleration of any such indebtedness. 

Upon the occurrence of an Event of Default, the Holder shall have then, or at any time thereafter, all of the rights and remedies
afforded by the Uniform Commercial Code as from time to time in effect in the State of Delaware or afforded by other applicable law. 
  

	5.	General. 

  

	 	(a)	Successors and Assigns. This Note, and the obligations and rights of the Company hereunder, shall be binding upon and inure to the benefit of the Company, the
Holder, and their respective heirs, successors and permitted assigns. 

  

	 	(b)	Recourse. Recourse under this Note shall be to the Company and its assets only, and in no event to the officers, directors or shareholders of the Company.

  
 -6-

	 	(c)	Changes. Changes in or additions to this Note may be made or compliance with any term, covenant, agreement, condition or provision set forth herein may be
omitted or waived (either generally or in a particular instance and either retroactively or prospectively), only upon written consent of the Company and the Majority Noteholders. 

 

	 	(d)	Governing Law. This Note shall be governed by and construed in accordance with the law of the State of Delaware, excluding the body of law relating to conflict
of laws. Notwithstanding anything to the contrary contained herein, in no event may the effective rate of interest collected or received by the holder hereof exceed that which may be charged, collected or received by the holder under applicable law.

  

	 	(e)	 Notices. All notices, requests, consents and demands shall be made in writing and shall be mailed postage prepaid, or delivered by hand, to the
Company at the Company’s principal offices or to the Holder at the address of the Holder set forth in the Note Purchase Agreement or to such other address as may be furnished in writing to the other party hereto, and in addition may be
delivered by telex, telecopy, electronic mail or facsimile transmission. All notices, requests, consents and other communications hereunder shall be deemed to have been given either (i) if by hand, at the time of the delivery thereof to the
receiving party at the address of such party set forth above, (ii) if made by telex, telecopy, electronic mail or facsimile transmission, at the time that receipt thereof has been acknowledged by electronic confirmation or otherwise,
(iii) if sent by overnight courier, on the next business day following the day such notice is delivered to the courier service, or (iv) if sent by registered or certified mail, on the 3rd business day following the day such mailing is made.

  

	 	(f)	Jurisdiction. THE COMPANY AGREES THAT ANY SUIT FOR THE ENFORCEMENT OF THIS NOTE, THE SUBSCRIPTION AGREEMENT OR ANY OTHER RELATED DOCUMENT MAY BE BROUGHT IN THE
COURTS OF THE STATE OF NEW YORK OR ANY FEDERAL COURT SITTING THEREIN AND CONSENTS TO THE NONEXCLUSIVE JURISDICTION OF SUCH COURTS AND SERVICE OF PROCESS IN ANY SUCH SUIT BEING MADE UPON THE COMPANY AT ITS PRINCIPAL OFFICES. THE COMPANY HEREBY WAIVES
ANY OBJECTION THAT IT MAY NOW OR HEREAFTER HAVE TO THE VENUE OF ANY SUCH SUIT OR ANY SUCH COURT OR THAT SUCH SUIT IS BROUGHT IN AN INCONVENIENT COURT. 

  

	 	(g)	Trial by Jury. The Company hereby waives its right to a jury trial with respect to any action or claim arising out of any dispute in connection with this Note,
any rights or obligations hereunder or the performance of such rights and obligations. 

  

	 	(h)	 To the extent permitted by applicable law, the Company shall not assert, and hereby waives, any claim against any Noteholder and their respective
affiliates, directors, employees, attorneys, agents or sub-agents, for special, indirect, consequential or punitive damages arising out of, in connection with, as a result of

  
 -7-

	 	
or related to, this Note, the transactions contemplated hereby or thereby, the Loan or the use of the proceeds thereof. 

[Remainder of Page Intentionally Left Blank] 

  
 -8-

 IN WITNESS WHEREOF, this Note has been executed and delivered on the date first above
written by the duly authorized representative of the Company. 
  

			
	RIB-X PHARMACEUTICALS, INC.
		
	By:	 	  

		
	Name:	 	  

		
	Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00196-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00196-of-00352.parquet"}]]